Mantle Cell Lymphoma (MCL) Recruiting Phase 3 Trials for Ibrutinib (DB09053)

Also known as: Lymphoma, Mantle-Cell / Mantle Cell Lymphoma / Mantle-Cell Lymphoma / Lymphoma, Mantle- Cell / Lymphoma, Mantle Cell / Mantle-Cell Lymphomas / B cell lymphoma / Centrocytic lymphoma / Mantle cell lymphoma NOS / Mantle cell lymphomas

IndicationStatusPhase
DBCOND0071979 (Mantle Cell Lymphoma (MCL))Recruiting3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03112174Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO)Treatment
NCT02991638Efficacy and Safety of Ibrutinib in Patients With CLL and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus CarriersTreatment
NCT02858258ASCT After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell LymphomaTreatment